Cargando…
PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies
SIMPLE SUMMARY: Positron emission tomography (PET), typically combined with computed tomography (CT), has become a critical advanced imaging technique in oncology. With PET-CT, a radioactive molecule (radiotracer) is injected in the bloodstream and localizes to sites of tumor because of specific cel...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179927/ https://www.ncbi.nlm.nih.gov/pubmed/35681647 http://dx.doi.org/10.3390/cancers14112668 |
_version_ | 1784723393357021184 |
---|---|
author | Koppula, Bhasker R. Fine, Gabriel C. Salem, Ahmed Ebada Covington, Matthew F. Wiggins, Richard H. Hoffman, John M. Morton, Kathryn A. |
author_facet | Koppula, Bhasker R. Fine, Gabriel C. Salem, Ahmed Ebada Covington, Matthew F. Wiggins, Richard H. Hoffman, John M. Morton, Kathryn A. |
author_sort | Koppula, Bhasker R. |
collection | PubMed |
description | SIMPLE SUMMARY: Positron emission tomography (PET), typically combined with computed tomography (CT), has become a critical advanced imaging technique in oncology. With PET-CT, a radioactive molecule (radiotracer) is injected in the bloodstream and localizes to sites of tumor because of specific cellular features of the tumor that accumulate the targeting radiotracer. The CT scan, performed at the same time, provides information to facilitate the characterization of radioactivity from deep or dense structures, and to provide detailed anatomic information. PET-CT has a variety of applications in oncology, including staging, therapeutic response assessment, restaging and surveillance. This series of six review articles provides an overview of the value, applications, and imaging interpretive strategies of PET-CT in the more common adult malignancies. The third report in this series provides a review of PET-CT imaging in gastrointestinal malignancies. ABSTRACT: PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and longitudinal surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, and the potential pitfalls and nuances that characterize these applications. In the third of these review articles, key tumor-specific clinical information and representative PET-CT images are provided to outline the role that PET-CT plays in the management of patients with gastrointestinal malignancies. The focus is on the use of (18)F fluorodeoxyglucose (FDG), rather than on research radiopharmaceuticals under development. Many different types of gastrointestinal tumors exist, both pediatric and adult. A discussion of the role of FDG PET-CT for all of these is beyond the scope of this review. Rather, this article focuses on the most common adult gastrointestinal malignancies that may be encountered in clinical practice. The information provided here will provide information outlining the appropriate role of PET-CT in the clinical management of patients with gastrointestinal malignancies for healthcare professionals caring for adult cancer patients. It also addresses the nuances and provides interpretive guidance related to PET-CT for imaging providers, including radiologists, nuclear medicine physicians and their trainees. |
format | Online Article Text |
id | pubmed-9179927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91799272022-06-10 PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies Koppula, Bhasker R. Fine, Gabriel C. Salem, Ahmed Ebada Covington, Matthew F. Wiggins, Richard H. Hoffman, John M. Morton, Kathryn A. Cancers (Basel) Review SIMPLE SUMMARY: Positron emission tomography (PET), typically combined with computed tomography (CT), has become a critical advanced imaging technique in oncology. With PET-CT, a radioactive molecule (radiotracer) is injected in the bloodstream and localizes to sites of tumor because of specific cellular features of the tumor that accumulate the targeting radiotracer. The CT scan, performed at the same time, provides information to facilitate the characterization of radioactivity from deep or dense structures, and to provide detailed anatomic information. PET-CT has a variety of applications in oncology, including staging, therapeutic response assessment, restaging and surveillance. This series of six review articles provides an overview of the value, applications, and imaging interpretive strategies of PET-CT in the more common adult malignancies. The third report in this series provides a review of PET-CT imaging in gastrointestinal malignancies. ABSTRACT: PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and longitudinal surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, and the potential pitfalls and nuances that characterize these applications. In the third of these review articles, key tumor-specific clinical information and representative PET-CT images are provided to outline the role that PET-CT plays in the management of patients with gastrointestinal malignancies. The focus is on the use of (18)F fluorodeoxyglucose (FDG), rather than on research radiopharmaceuticals under development. Many different types of gastrointestinal tumors exist, both pediatric and adult. A discussion of the role of FDG PET-CT for all of these is beyond the scope of this review. Rather, this article focuses on the most common adult gastrointestinal malignancies that may be encountered in clinical practice. The information provided here will provide information outlining the appropriate role of PET-CT in the clinical management of patients with gastrointestinal malignancies for healthcare professionals caring for adult cancer patients. It also addresses the nuances and provides interpretive guidance related to PET-CT for imaging providers, including radiologists, nuclear medicine physicians and their trainees. MDPI 2022-05-27 /pmc/articles/PMC9179927/ /pubmed/35681647 http://dx.doi.org/10.3390/cancers14112668 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Koppula, Bhasker R. Fine, Gabriel C. Salem, Ahmed Ebada Covington, Matthew F. Wiggins, Richard H. Hoffman, John M. Morton, Kathryn A. PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies |
title | PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies |
title_full | PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies |
title_fullStr | PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies |
title_full_unstemmed | PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies |
title_short | PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies |
title_sort | pet-ct in clinical adult oncology: iii. gastrointestinal malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179927/ https://www.ncbi.nlm.nih.gov/pubmed/35681647 http://dx.doi.org/10.3390/cancers14112668 |
work_keys_str_mv | AT koppulabhaskerr petctinclinicaladultoncologyiiigastrointestinalmalignancies AT finegabrielc petctinclinicaladultoncologyiiigastrointestinalmalignancies AT salemahmedebada petctinclinicaladultoncologyiiigastrointestinalmalignancies AT covingtonmatthewf petctinclinicaladultoncologyiiigastrointestinalmalignancies AT wigginsrichardh petctinclinicaladultoncologyiiigastrointestinalmalignancies AT hoffmanjohnm petctinclinicaladultoncologyiiigastrointestinalmalignancies AT mortonkathryna petctinclinicaladultoncologyiiigastrointestinalmalignancies |